Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
close
Save to Existing Project
Save to a New Project
PON1 as a Detoxification Agent
Yeda R&D Co. Ltd Israel flag Israel
Abstract ID:
An enzyme with improved anti-atherosclerotic and detoxiftying activities....
Contact Galit Mazooz, ph.d.
Participants
You
Email me a copy of this message

An enzyme with improved anti-atherosclerotic and detoxiftying activities.
The enzyme Paraoxonase 1 (PON1) resides on HDL in the blood. The levels of PON1 and its catalytic proficiency appear to have a major impact on susceptibility to atherosclerosis, cardiac and vascular diseases, cholesterol reducing drugs and various toxins and pollutants, such as organophosphates (pesticides and nerve gases). However, when trying to use the human PON1 one encounters several problems, including its insolublilty and the lack of recombinant PON variants that can be expressed and manipulated in bacteria. The current technology offers new, genetically-engineered PON1 variants that are expressed in a fully functional form, at multi-miligram quantities and unprecedented purity.


Applications






    • PON1 variants with improved anti-atherosclerotic activities for the prevention of restenosis that follows the placement of stents (and other devices) in arteries





    • Diagnostics of risk factors and genetic polymorphisms for atherosclerosis





    • Detoxification and decontamination of a variety of reagents (e.g. organophosphates)





Advantages






    • Improved features of the recombinant PON1 enzyme compared to the wild type enzyme (e.g. increased activity, solubility and cholesterol efflux in macrophages)





    • Recombinant PON1 can be expressed and manipulated in large quantities in bacteria





Technology's Essence


PON1 resides within the cholesterol-carrying particles HDL and exhibits a multitude of activities related to the metabolism of drugs, lipids and other molecules associated with atherosclerotic vascular and cardiac diseases. The outlined technology utilized directed evolution in the laboratory, which yielded a series of variants that are 50-200 fold more proficient than native PON1 in different physiologically relevant tasks


Licensing Status

GO PREMIUM TO GET PATENT INFORMATION
FEATURED
Last Updated May 2016
Technology Type DIAGNOSTIC
Phase of Development EARLY STAGE
CORPORATION